Development and improvement of Chinese Haemovigilance Network from 2018 to 2023.

IF 1.6 4区医学 Q3 HEMATOLOGY

Vox Sanguinis Pub Date : 2026-09-01 Epub Date: 2026-06-17 DOI:10.1111/vox.70303

Ling Li, Bo Pan, Bangqiang Zhu, Hui Huang, Xiaoyu Guan, Yaling Zhou, Liu He, Jue Wang, Zhong Liu

{"title":"Development and improvement of Chinese Haemovigilance Network from 2018 to 2023.","authors":"Ling Li, Bo Pan, Bangqiang Zhu, Hui Huang, Xiaoyu Guan, Yaling Zhou, Liu He, Jue Wang, Zhong Liu","doi":"10.1111/vox.70303","DOIUrl":null,"url":null,"abstract":"Background and objectives: This study aimed to investigate the evolving data trends of the Chinese Haemovigilance Network (CHN) and provide insights into its future development.Materials and methods: Data were collected from the CHN covering the period of 2018-2023. The data were subdivided into three phases and analysed from several aspects. We also compared the percentage distribution of adverse transfusion reactions (ATRs) between the CHN and other national haemovigilance reports.Results: Overall, the number of hospitals participating in reporting ATRs has increased, from a total of 188 in 2018-2019 to 206 in 2020-2021 and 222 in 2022-2023. The CHN received 6410 ATRs cases: 1915 in 2018-2019, 2265 in 2020-2021 and 2230 in 2022-2023. The reports for all three phases covered 11 types of ATRs that involved transfusion of nine blood components. The highest percentage of ATRs was caused by apheresis platelets (591/1915 in 2018-2019, 756/2265 in 2020-2021 and 760/2230 in 2022-2023). In terms of ATR severity, no severity was overwhelming (91.70% in 2018-2019, 95.74% in 2020-2021 and 93.34% in 2022-2023). The CHN report showed a higher proportion of allergic reactions compared to serious hazards of transfusion. Similarly, differences in the distribution of ATRs were also observed between the CHN system and both the Australian and transfusion and transplantation reactions in patients haemovigilance systems.Conclusion: Over the past 6 years, the CHN has established a relatively advanced haemovigilance system. Comparison of the CHN and other national haemovigilance reports revealed differences in the classification and percentage distribution of ATRs, underscoring the need for standardized reporting to enhance global transfusion safety.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1376-1384"},"PeriodicalIF":1.6000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563488/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70303","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: This study aimed to investigate the evolving data trends of the Chinese Haemovigilance Network (CHN) and provide insights into its future development.

Materials and methods: Data were collected from the CHN covering the period of 2018-2023. The data were subdivided into three phases and analysed from several aspects. We also compared the percentage distribution of adverse transfusion reactions (ATRs) between the CHN and other national haemovigilance reports.

Results: Overall, the number of hospitals participating in reporting ATRs has increased, from a total of 188 in 2018-2019 to 206 in 2020-2021 and 222 in 2022-2023. The CHN received 6410 ATRs cases: 1915 in 2018-2019, 2265 in 2020-2021 and 2230 in 2022-2023. The reports for all three phases covered 11 types of ATRs that involved transfusion of nine blood components. The highest percentage of ATRs was caused by apheresis platelets (591/1915 in 2018-2019, 756/2265 in 2020-2021 and 760/2230 in 2022-2023). In terms of ATR severity, no severity was overwhelming (91.70% in 2018-2019, 95.74% in 2020-2021 and 93.34% in 2022-2023). The CHN report showed a higher proportion of allergic reactions compared to serious hazards of transfusion. Similarly, differences in the distribution of ATRs were also observed between the CHN system and both the Australian and transfusion and transplantation reactions in patients haemovigilance systems.

Conclusion: Over the past 6 years, the CHN has established a relatively advanced haemovigilance system. Comparison of the CHN and other national haemovigilance reports revealed differences in the classification and percentage distribution of ATRs, underscoring the need for standardized reporting to enhance global transfusion safety.

查看原文本刊更多论文

2018 - 2023年中国血液警戒网络的发展与完善

背景与目的：本研究旨在探讨中国血液警戒网络（CHN）数据的发展趋势，并为其未来的发展提供见解。资料和方法：数据收集自中国人口统计中心，时间为2018-2023年。数据被细分为三个阶段，并从几个方面进行分析。我们还比较了CHN和其他国家血液警戒报告之间输血不良反应（ATRs）的百分比分布。结果：总体而言，参与报告atr的医院数量有所增加，从2018-2019年的188家增加到2020-2021年的206家和2022-2023年的222家。中国共收到6410例atr病例：2018-2019年1915例，2020-2021年2265例，2022-2023年2230例。所有三个阶段的报告涵盖了涉及9种血液成分输血的11种atr。血小板单采引起的atr比例最高（2018-2019年为591/1915,2020-2021年为756/2265,2022-2023年为760/2230）。在ATR严重程度方面，无严重程度占压倒性优势（2018-2019年为91.70%，2020-2021年为95.74%，2022-2023年为93.34%）。CHN报告显示，与输血的严重危害相比，过敏反应的比例更高。同样，在CHN系统和澳大利亚以及患者血液警戒系统的输血和移植反应之间也观察到atr分布的差异。结论：在过去的6年里，CHN已经建立了相对先进的血液警戒系统。CHN和其他国家血液警戒报告的比较揭示了atr分类和百分比分布的差异，强调了标准化报告以加强全球输血安全的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vox Sanguinis 医学-血液学

CiteScore

4.40

自引率

11.10%

发文量

156

审稿时长

6-12 weeks

期刊介绍： Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections: 1) Transfusion - Transmitted Disease and its Prevention: Identification and epidemiology of infectious agents transmissible by blood; Bacterial contamination of blood components; Donor recruitment and selection methods; Pathogen inactivation. 2) Blood Component Collection and Production: Blood collection methods and devices (including apheresis); Plasma fractionation techniques and plasma derivatives; Preparation of labile blood components; Inventory management; Hematopoietic progenitor cell collection and storage; Collection and storage of tissues; Quality management and good manufacturing practice; Automation and information technology. 3) Transfusion Medicine and New Therapies: Transfusion thresholds and audits; Haemovigilance; Clinical trials regarding appropriate haemotherapy; Non-infectious adverse affects of transfusion; Therapeutic apheresis; Support of transplant patients; Gene therapy and immunotherapy. 4) Immunohaematology and Immunogenetics: Autoimmunity in haematology; Alloimmunity of blood; Pre-transfusion testing; Immunodiagnostics; Immunobiology; Complement in immunohaematology; Blood typing reagents; Genetic markers of blood cells and serum proteins: polymorphisms and function; Genetic markers and disease; Parentage testing and forensic immunohaematology. 5) Cellular Therapy: Cell-based therapies; Stem cell sources; Stem cell processing and storage; Stem cell products; Stem cell plasticity; Regenerative medicine with cells; Cellular immunotherapy; Molecular therapy; Gene therapy.